These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 20857352)

  • 21. An Update on Poly(ADP-ribose)polymerase-1 (PARP-1) Inhibitors: Opportunities and Challenges in Cancer Therapy.
    Wang YQ; Wang PY; Wang YT; Yang GF; Zhang A; Miao ZH
    J Med Chem; 2016 Nov; 59(21):9575-9598. PubMed ID: 27416328
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PARP inhibitors and cancer therapy - early results and potential applications.
    Jones C; Plummer ER
    Br J Radiol; 2008 Oct; 81 Spec No 1():S2-5. PubMed ID: 18819994
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Poly (ADP-ribose) polymerase inhibitors in cancer treatment.
    Mason KA; Raju U; Buchholz TA; Wang L; Milas ZL; Milas L
    Am J Clin Oncol; 2014 Feb; 37(1):90-100. PubMed ID: 22495455
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of poly(ADP-ribose) polymerase in cancer.
    Plummer ER
    Curr Opin Pharmacol; 2006 Aug; 6(4):364-8. PubMed ID: 16753340
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [PARP inhibitors for cancer therapy].
    Saito H; Miki Y
    Gan To Kagaku Ryoho; 2011 Jan; 38(1):12-8. PubMed ID: 21368455
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PARP and PARG inhibitors in cancer treatment.
    Slade D
    Genes Dev; 2020 Mar; 34(5-6):360-394. PubMed ID: 32029455
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting poly (ADP) ribose polymerase I (PARP-1) and PARP-1 interacting proteins for cancer treatment.
    Sakamoto-Hojo ET; Balajee AS
    Anticancer Agents Med Chem; 2008 May; 8(4):402-16. PubMed ID: 18473725
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PARP inhibitors for cancer therapy.
    Curtin NJ
    Expert Rev Mol Med; 2005 Mar; 7(4):1-20. PubMed ID: 15836799
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A comprehensive look of poly(ADP-ribose) polymerase inhibition strategies and future directions for cancer therapy.
    Kumar C; Rani N; Velan Lakshmi PT; Arunachalam A
    Future Med Chem; 2017 Jan; 9(1):37-60. PubMed ID: 27995810
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies.
    Kummar S; Kinders R; Gutierrez ME; Rubinstein L; Parchment RE; Phillips LR; Ji J; Monks A; Low JA; Chen A; Murgo AJ; Collins J; Steinberg SM; Eliopoulos H; Giranda VL; Gordon G; Helman L; Wiltrout R; Tomaszewski JE; Doroshow JH
    J Clin Oncol; 2009 Jun; 27(16):2705-11. PubMed ID: 19364967
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of inhibitors of poly(ADP-ribose) polymerase as resistance-modifying agents in cancer therapy.
    Griffin RJ; Curtin NJ; Newell DR; Golding BT; Durkacz BW; Calvert AH
    Biochimie; 1995; 77(6):408-22. PubMed ID: 7578423
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Research progresses of the PARP inhibitors for the treatment of cancer].
    He YJ; Liu RH; Ning CQ; Yu NF
    Yao Xue Xue Bao; 2013 May; 48(5):655-60. PubMed ID: 23888686
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PARP inhibitors in cancer therapy: two modes of attack on the cancer cell widening the clinical applications.
    Drew Y; Plummer R
    Drug Resist Updat; 2009 Dec; 12(6):153-6. PubMed ID: 19939726
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The therapeutic potential of poly(ADP-ribose) polymerase inhibitors.
    Virág L; Szabó C
    Pharmacol Rev; 2002 Sep; 54(3):375-429. PubMed ID: 12223530
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predictive biomarkers for cancer therapy with PARP inhibitors.
    Michels J; Vitale I; Saparbaev M; Castedo M; Kroemer G
    Oncogene; 2014 Jul; 33(30):3894-907. PubMed ID: 24037533
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Poly(ADP-ribose) polymerase (PARP) inhibitors in BRCA1/2 cancer therapy].
    Kluzek K; Białkowska A; Koczorowska A; Zdzienicka MZ
    Postepy Hig Med Dosw (Online); 2012 Jun; 66():372-84. PubMed ID: 22706123
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Putting poly (ADP-ribose) polymerase and other DNA repair inhibitors into clinical practice.
    Helleday T
    Curr Opin Oncol; 2013 Nov; 25(6):609-14. PubMed ID: 24097104
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PARP Inhibition in Cancer: An Update on Clinical Development.
    Sachdev E; Tabatabai R; Roy V; Rimel BJ; Mita MM
    Target Oncol; 2019 Dec; 14(6):657-679. PubMed ID: 31625002
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Poly(ADP-ribose) polymerase activity and inhibition in cancer.
    Dulaney C; Marcrom S; Stanley J; Yang ES
    Semin Cell Dev Biol; 2017 Mar; 63():144-153. PubMed ID: 28087320
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Update on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatment.
    Papa A; Caruso D; Strudel M; Tomao S; Tomao F
    J Transl Med; 2016 Sep; 14():267. PubMed ID: 27634150
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.